How many insider trades does FilingIQ track for PKTX?

FilingIQ tracks 220 Form 4 insider transactions for PKTX (ProtoKinetix, Inc.), covering filings from Feb 26, 2015 onwards. 0 of those were filed in the last 90 days.

Are PKTX insiders net buyers or net sellers?

Across the full Form 4 history for PKTX, 196 transactions (89%) were open-market purchases and 4 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PKTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PKTX in?

ProtoKinetix, Inc. (PKTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.07M.

PKTX insider trading

OTC Markets OTCPK Healthcare

ProtoKinetix, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

220

Last 90 days

Buys / sells

89% / 2%

Market cap

$3.07M

About ProtoKinetix, Inc.

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications comprising targeted health care solutions, as well as AAGPs are used for applications in ophthalmology, dermatology, transplants, and biomanufacturing areas. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.

Company website: www.protokinetix.com

PKTX insider activity at a glance

FilingIQ has scored 220 insider transactions for PKTX since Feb 26, 2015. The most recent filing in our index is dated Sep 26, 2024.

Across the full history, 196 open-market purchases and 4 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PKTX insider trades is 57.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PKTX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for PKTX?: FilingIQ tracks 220 Form 4 insider transactions for PKTX (ProtoKinetix, Inc.), covering filings from Feb 26, 2015 onwards. 0 of those were filed in the last 90 days.
Are PKTX insiders net buyers or net sellers?: Across the full Form 4 history for PKTX, 196 transactions (89%) were open-market purchases and 4 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PKTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PKTX in?: ProtoKinetix, Inc. (PKTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.07M.

Methodology & sources

Every PKTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.